AFT Pharmaceuticals - Public Comps and Valuation Multiples

AFT Pharmaceuticals Overview

About AFT Pharmaceuticals

AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.

Founded

1997

HQ

Employees

119

Website

aftpharm.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $119M

LTM EBITDA $11.6M

EV

$209M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

AFT Pharmaceuticals Financials

As of September 2025, AFT Pharmaceuticals reported last 12-month revenue of $119M and EBITDA of $11.6M.

In the same period, AFT Pharmaceuticals generated $52.4M in LTM gross profit and $6.8M in net income.

See AFT Pharmaceuticals valuation multiples based on analyst estimates

AFT Pharmaceuticals P&L

In the most recent fiscal year, AFT Pharmaceuticals reported revenue of $117M and EBITDA of $12.3M.

AFT Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

See AFT Pharmaceuticals valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$119M	XXX	$117M	XXX	XXX	XXX
Gross Profit	$52.4M	XXX	$51.0M	XXX	XXX	XXX
Gross Margin	44%	XXX	43%	XXX	XXX	XXX
EBITDA	$11.6M	XXX	$12.3M	XXX	XXX	XXX
EBITDA Margin	10%	XXX	10%	XXX	XXX	XXX
EBIT	$10.1M	XXX	$6.7M	XXX	XXX	XXX
EBIT Margin	8%	XXX	6%	XXX	XXX	XXX
Net Profit	$6.8M	XXX	$6.8M	XXX	XXX	XXX
Net Margin	6%	XXX	6%	XXX	XXX	XXX
Net Debt	XXX	XXX	$8.9M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for AFT Pharmaceuticals including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $119M. EBITDA for the last twelve months was $11.6M. In the most recent fiscal year, AFT Pharmaceuticals achieved $117M in revenue and $12.3M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$119M	Analyst estimates available to subscribers	$117M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$52.4M	Analyst estimates available to subscribers	$51.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	44.1% gross margin	Analyst estimates available to subscribers	43.4% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$11.6M	Analyst estimates available to subscribers	$12.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	9.8% EBITDA margin	Analyst estimates available to subscribers	10.5% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$10.1M	Analyst estimates available to subscribers	$6.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	8.5% EBIT margin	Analyst estimates available to subscribers	5.7% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$6.8M	Analyst estimates available to subscribers	$6.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	5.8% net profit margin	Analyst estimates available to subscribers	5.8% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$8.9M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for AFT Pharmaceuticals

This financial data table provides comprehensive performance metrics for AFT Pharmaceuticals, a company based in New Zealand. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

AFT Pharmaceuticals generated $119M in revenue over the last twelve months.
The company achieved $11.6M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $52.4M.
Net income over the last twelve months reached $6.8M.

Fiscal Year Performance

In the most recent fiscal year, AFT Pharmaceuticals reported $117M in total revenue.
Fiscal year EBITDA was $12.3M.
The company maintained a gross profit margin of 43.4% in the most recent fiscal year.
EBITDA margin for the fiscal year was 10.5%.
Net profit margin reached 5.8% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for AFT Pharmaceuticals. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

AFT Pharmaceuticals Stock Performance

AFT Pharmaceuticals has current market cap of NZD 346M (or $198M), and EV of NZD 365M (or $209M).

Market Cap Evolution

AFT Pharmaceuticals Stock Data

As of October 17, 2025, AFT Pharmaceuticals's stock price is NZD 3 (or $2).

See AFT Pharmaceuticals trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$209M	$198M	XXX	XXX	XXX	XXX	$0.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

AFT Pharmaceuticals Valuation Multiples

AFT Pharmaceuticals's trades at 1.8x EV/Revenue multiple, and 15.8x EV/EBITDA.

See valuation multiples for AFT Pharmaceuticals and 15K+ public comps

AFT Pharmaceuticals Financial Valuation Multiples

As of October 17, 2025, AFT Pharmaceuticals has market cap of $198M and EV of $209M.

Equity research analysts estimate AFT Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

AFT Pharmaceuticals has a P/E ratio of 28.9x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$198M	XXX	$198M	XXX	XXX	XXX
EV (current)	$209M	XXX	$209M	XXX	XXX	XXX
EV/Revenue	1.8x	XXX	1.8x	XXX	XXX	XXX
EV/EBITDA	18.0x	XXX	15.8x	XXX	XXX	XXX
EV/EBIT	20.7x	XXX	26.3x	XXX	XXX	XXX
EV/Gross Profit	4.0x	XXX	n/a	XXX	XXX	XXX
P/E	28.9x	XXX	26.9x	XXX	XXX	XXX
EV/FCF	n/a	XXX	38.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get AFT Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

AFT Pharmaceuticals Margins & Growth Rates

AFT Pharmaceuticals's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.4M for the same period.

AFT Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

AFT Pharmaceuticals's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for AFT Pharmaceuticals and other 15K+ public comps

AFT Pharmaceuticals Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	10%	XXX	11%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$1.0M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.4M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	25%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	6%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	38%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial